Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study

Overview of attention for article published in International Journal of Hematology, June 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 22 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 1 X post from an account with 14,844 followers.

Study of #Darzalex in Japanese #myeloma pts shows 44% response rate, 6 & 9.5 month PFS in 8 & 16 mg/kg cohorts: https://t.co/Pow9RMnlS8. https://t.co/5d8MS96C5D

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.